Yingtao Lin

机构：Fujian Medical University, China Pharmaceutical University, Nanjing Health and Health Commission, First Affiliated Hospital of Fujian Medical University, Center for Global Health, Fujian Provincial Cancer Hospital, Nanjing Medical University · ORCID：0000-0001-9168-0491

发表论文 23 篇 · 总被引 119 次 · h-index 7

代表论文

• Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China (2024 · International Journal of Clinical Pharmacy · 被引 16)
• Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (2021 · Cancer Management and Research · 被引 14)
• Cost-effectiveness of PD-1 inhibitors combined with chemotherapy for first-line treatment of oesophageal squamous cell carcinoma in China: a comprehensive analysis (2025 · Annals of Medicine · 被引 12)
• Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer (2024 · Frontiers in Immunology · 被引 12)
• Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China (2022 · Frontiers in Public Health · 被引 12)
• Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China (2023 · Frontiers in Immunology · 被引 11)